This funding opportunity uses the R21 research grant mechanism.
The award ceiling for this funding opportunity is
This funding opportunity is open to any entity such as state, county, city, township and special district governments; Native American tribal governments and organizations; institutions of higher education; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; nonprofits; for profit organizations; small businesses; eligible agencies of the federal government; and faith-based or community-based organizations.
A funding opportunity notice from the NIH states: "Specific areas of research interest under this FOA [Funding Opportunity Announcement] include, but are not limited to, the following: 1. Development of innovative technologies and platforms for oral pediatric formulations for poorly soluble drugs, unpalatable drugs and for drugs requiring reconstitutable dosage forms. These technologies include taste masking and the use of novel excipients; 2. Use of a material science approach to overcome solubility limitations of pediatric drugs, increase bioavailability, decrease excipients' exposure and provide effective taste masking; 3. Develop novel methods for the design of solubility enhancing formulations of highly insoluble pediatrics drugs based on physicochemical and molecular interactions of a drug/stabilizer system; 4. Development of novel therapeutic or theranostic nanodevices with application in pediatrics; 5. Development of animal models for taste assessment with comparison to electronic tongue as well as more traditional sensory analysis; 6. Development of standardized methods for testing drug formulations in children and adult panels; 7. Studies to evaluate the value of electronic tongue to quantify bitterness and taste masking efficiency in the development of pediatric formulations; 8. Study of effect of different textures, granularity and smell of dosage forms in the acceptability of pediatric formulations; 9. Determination of the reliability of using the Biopharmaceutical Classification System in newborns and young infants; 10. Study of the effect in infancy of the functional ontogeny of the gastrointestinal tract and of feedings on the dissolution, solubilization and absorption of different types of pediatric dosage forms; 11. Development of nanosized formulations to optimize efficacy and minimize toxicity of off patent pediatric drugs of narrow therapeutic index; 12. Performance of studies on cross-cultural flavor preferences and bitter taste sensitivity in children; 13. Performance of psychophysical research on the chemical senses to determine what types of adult sensory panels and methods are most appropriate for predicting acceptance/compliance in the pediatric population; 14. Performance of studies on excipients used in pediatric formulations, assessing interaction of excipients with drugs and with other excipients in different pediatric formulations; 15. Development of non-invasive devices for evaluating adherence to chronic therapy in life- threatening conditions (e.g. HIV, asthma, diabetes, liver and kidney transplant patients); and 16. Development of novel approaches for oral mucosal, transdermal, nasal, ocular and pulmonary drug delivery systems and device technologies."
The funding opportunity number is PAR-13-326 (CFDA Nos. 93.173 & 93.865). The application closing date is
For more information about
Most Popular Stories
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Allstate Seeks to Invest in Minority Firms
- Stolen Cobalt-60 Recovered in Mexico
- SpaceX's Satellite Launch Is 'Game-Changer'
- White House Pushes to Extend Unemployment Benefits
- Latin Music Conference Turns 25
- First-time Jobless Claims Drop Below 300,000
- Sarmiento to Handle Greeley Latin Ops
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Calif. Likes Christie, Says Tea Party's a Drag